MPM BioImpact
高管
查看带有其 29 名主要高管的组织结构图
MPM BioImpact 搜索最多的简介
- Christiana Bardon, Managing Partner
- Ansbert Gadicke, Managing Partner
- Matthew Roden, Entrepreneur Partner
高管在MPM BioImpact变化
- Brian Shuster已作为Entrepreneur Partner加入公司 (新闻发布的2025一月9号).
- Frank Neumann已作为Entrepreneur Partner, BioImpact加入公司 (新闻发布的2024四月12号).
创建提醒
跟踪 MPM BioImpact 的高管变动
基金
MPM BioImpact 拥有 1,536 家竞争者，其中包括 BlackRock (美国(美洲))、Vanguard (美国(美洲)) 和 Blackstone Group (美国(美洲))。
Popular M&A news in 基金
- Cansortium 已收购 RIV Capital (公布2024十二月20号).
- RIV Capital and Cansortium have announced they will merge (公布2024十月14号)..
- Janus Henderson Group 已收购 Victory Park Capital (公布2024十月7号).
基金 行业的其他推荐联系人
消息
MPM BioImpact 的最新新闻稿
- Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation | Syndax Pharmaceuticals, Inc.
- MPM BioImpact Appoints Michael Ehlers, M.D., Ph.D., Experienced R&D Leader and Accomplished Biotechnology Executive, as Entrepreneur Partner
- AKTIS ONCOLOGY ANNOUNCES $175 MILLION OVERSUBSCRIBED SERIES B FINANCING TO FURTHER ADVANCE ITS PROPRIETARY RADIOPHARMACEUTICAL PIPELINE - Aktis
- AKTIS ONCOLOGY APPOINTS AKOS CZIBERE, MD, PhD, CHIEF MEDICAL OFFICER - Aktis
- NextPoint Therapeutics Chief Executive Officer Ivan Cheung Named to the 2024 TIME100 Health List
- MPM BioImpact | News
- Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline | Frontier Medicine
- ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer
- NextPoint Therapeutics Announces Closing of Series B Financing Extension Led by Catalio Capital Management
- Press Release | Firefly Bio Debuts With $94 Million Series A Financing
- View more press releases Close
通过电子邮件
